Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. – The study met its primary objective of demonstrating statistically greater improvement from baseline in Eczema Area and Severity Index score at 16 weeks versus placebo – Patients receiving KHK4083/AMG 451 showed statistically greater improvements in additional secondary efficacy endpoints versus placebo – KHK4083/AMG 451 also showed progressive improvement in efficacy beyond 16 weeks TOKYO & THOUSAND OAKS, Calif, (BUSINESS WIRE) 02.10.2021 Kyowa Kirin Co., Ltd. (TSE:4151) and Amgen (NASDAQ: AMGN) today announced that positive data from a Phase 2 study of KHK4083/AMG 451 …

Read the source article at finanztreff.de
2021-10-02 01:00:00